7VG
SKAN Group AG, together with its subsidiaries, provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally. It operates in two segments, Equipment and Solutions; and Services and Consumables. The company offers accessories, biological indicators, digital ventures, isolators, cleanroom, laminar f… Read more
7VG (7VG) - Net Assets
Latest net assets as of June 2025: €183.43 Million EUR
Based on the latest financial reports, 7VG (7VG) has net assets worth €183.43 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€381.49 Million) and total liabilities (€198.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €183.43 Million |
| % of Total Assets | 48.08% |
| Annual Growth Rate | 5.19% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.07 |
7VG - Net Assets Trend (2021–2024)
This chart illustrates how 7VG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 7VG (2021–2024)
The table below shows the annual net assets of 7VG from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €202.56 Million | +14.86% |
| 2023-12-31 | €176.36 Million | +6.50% |
| 2022-12-31 | €165.59 Million | -4.83% |
| 2021-12-31 | €174.01 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 7VG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 130.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €82.59 Million | 42.10% |
| Other Components | €113.57 Million | 57.90% |
| Total Equity | €196.16 Million | 100.00% |
7VG Competitors by Market Cap
The table below lists competitors of 7VG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SonoScape Medical Corp
SHE:300633
|
$684.92 Million |
|
Qingdao Yunlu Advanced Materials Technology Co. Ltd. A
SHG:688190
|
$685.12 Million |
|
Shandong Yisheng Livestock & Poultry Breeding Co Ltd
SHE:002458
|
$685.16 Million |
|
Guild Holdings Co
NYSE:GHLD
|
$685.20 Million |
|
Línea Directa Aseguradora S.A
PINK:LNDAF
|
$684.86 Million |
|
Irish Continental Group plc
PINK:IRCUF
|
$684.83 Million |
|
Andlauer Healthcare Gr
TO:AND
|
$684.64 Million |
|
Winpak Ltd
PINK:WIPKF
|
$684.45 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 7VG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 169,232,000 to 196,159,000, a change of 26,927,000 (15.9%).
- Net income of 38,803,000 contributed positively to equity growth.
- Dividend payments of 7,869,000 reduced retained earnings.
- Other factors decreased equity by 4,007,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €38.80 Million | +19.78% |
| Dividends Paid | €7.87 Million | -4.01% |
| Other Changes | €-4.01 Million | -2.04% |
| Total Change | €- | 15.91% |
Book Value vs Market Value Analysis
This analysis compares 7VG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7.39x to 6.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €7.10 | €52.50 | x |
| 2022-12-31 | €7.00 | €52.50 | x |
| 2023-12-31 | €7.53 | €52.50 | x |
| 2024-12-31 | €8.72 | €52.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 7VG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.78%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.74%
- • Asset Turnover: 0.94x
- • Equity Multiplier: 1.96x
- Recent ROE (19.78%) is above the historical average (13.51%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 6.65% | 4.53% | 0.71x | 2.08x | €-5.36 Million |
| 2022 | 12.07% | 6.86% | 0.71x | 2.47x | €3.26 Million |
| 2023 | 15.55% | 8.22% | 0.86x | 2.21x | €9.39 Million |
| 2024 | 19.78% | 10.74% | 0.94x | 1.96x | €19.19 Million |
Industry Comparison
This section compares 7VG's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $10,546,246,336
- Average return on equity (ROE) among peers: 3.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 7VG (7VG) | €183.43 Million | 6.65% | 1.08x | $684.88 Million |
| Modern Dental Group Limited (1MD) | $2.36 Billion | 15.30% | 0.55x | $193.75 Million |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $482.88 Million |
| Alcon Inc. (2U3) | $19.26 Billion | 1.95% | 0.45x | $33.73 Billion |
| Shofu Inc. (69W) | $35.51 Billion | 8.83% | 0.23x | $215.32 Million |
| Bio-gate AG (BIG1) | $4.25 Million | -42.46% | 0.46x | $2.79 Million |
| Paul Hartmann AG (PHH2) | $690.37 Million | 10.65% | 0.81x | $776.29 Million |
| Sartorius AG VZO O.N. (SRT) | $497.08 Million | 9.76% | 1.56x | $6.78 Billion |
| Shandong Weigao Group Medical Polymer Company Limited (UK2) | $25.34 Billion | 8.16% | 0.37x | $1.36 Billion |